All News

New Tool to Reduce Ownership Costs and Facilitate Manufacturer Documented Certification between Patients Eitan Group to Provide Demonstrations of Service Tool at MEDICA Trade Fair, November 18-21, Düsseldorf, Germany.

Top news of the day from across the health care landscape.

Study shows a significantly greater proportion of patients with Crohn disease who were administered ustekinumab every 8 weeks achieved a histologic response.

In 2019, the popularity of self-reported e-cigarette use was high among high school and middle school students, with many current e-cigarette users reporting frequent use and most of the exclusive users reporting use of flavored e-cigarettes.

Some fourth-year pharmacy students have brought new meaning to the phrase “back to basics,” by participating in an elective rotation at the Colonial Williamsburg apothecary.

Top news of the day from across the health care landscape.

Pegfilgrastim-bmez (Ziextenzo, Sandoz), a biosimilar to pegfilgrastim (Neulasta), is indicated to decrease the incidence of febrile neutropenia, a serious adverse effect of chemotherapy.

Study seeks to determine the prevalence and clinical significance of red blood cell-bound immunoglobulin G as detected by flow cytometry in polytransfused patients with thalassemia.

Influenza vaccine approved for use in adult patients 65 years and older.

Jesse C. Dresser, Esq explains how specialty pharmacists can educate and inform legislators on PBM reform at the NASP Annual Meeting in Washington, DC.

Dicyclomine Hydrochloride Injectable is the generic version of Bentyl from Allergan and is used to treat functional bowel or irritable bowel syndrome.

Why is KS experiencing hypertension?

The SELECT-PsA phase 3 study is the first to evaluate the efficacy and safety of upadacitinib in adult patients with active psoriatic arthritis.

Omeprazole magnesium, amoxicillin, and rifabutin (Talicia, RedHill Biopharma) is indicated for the treatment of Helicobacter pylori (H. pylori) infection in adults.

Top news of the day from across the health care landscape.

Advancements in the understanding of asthma pathophysiology has led to the discovery of defined asthma phenotypes and targeted interventions involving novel biologic therapies.

Three complement genes identified in a new study may serve as markers for monitoring and predicting the progression and severity of multiple sclerosis.

Although the levels of NDMA that was found through FDA testing are much lower than the levels that a few third-party investigators claimed, the report indicated that these levels exceed what the FDA considers acceptable for these medicines.

A recent study demonstrated that budesonide-formoterol is superior to albuterol for as-needed exacerbation prevention in mild asthma.

EZC Pak, the first physician formulated, tapered immune support pack, will be presented to millionaire and billionaire investors on ABC’s Shark Tank on Sunday, November 3, at 9 PM ET/8 PM CT.

Labeling, seals of approval, and ingredients should be considered when counseling patients about dietary supplements.

Texas oncologist Stephen Hahn, MD, is expected to receive the Trump administration’s nomination for the role of FDA Commissioner, a move that had been anticipated by federal insiders.

Top news of the week from Specialty Pharmacy Times.

The largest ever trial of postoperative radiotherapy in prostate cancer shows men may be spared the procedure after surgery.

Top news of the day from across the health care landscape

The Ensuring Seniors Access to Local Pharmacies Act, which was recently reintroduced, would allow more “preferred” pharmacies in medically underserved areas.

SunGen Pharma, the specialty pharmaceutical company, has received its eighth ANDA approval from the FDA.

Lumacaftor-ivacaftor (Orkambi) improves lung health in patients with cystic fibrosis who tolerate the treatment, but discontinuation rates may pose a risk of deterioration.

Officials from the FDA have allowed ObsEva to begin enrolling patients in IMPLANT 3, the U.S. pivotal Phase 3 clinical trial in nolasiban in women undergoing embryo transfer (ET) following in-vitro fertilization (IVF).

Top news of the day from across the health care landscape